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Stimuli-responsive nanogelsAbstract Nanogels are being explored as drug delivery agents for targeting cancer due to their easy
tailoring properties and ability to efﬁciently encapsulate therapeutics of diverse nature through sim-
ple mechanisms. Nanogels are proﬁciently internalized by the target cells, avoid accumulating in
nontarget tissues thereby lower the therapeutic dosage and minimize harmful side effects. However,
there is an urgent need for relevant clinical data from nanogels so as to allow translation of the
nanogel concept into a viable therapeutic application for the treatment of cancer. This review high-
lights some of the recent progress in nanogels as a carrier in the ﬁeld of nanomedicine for the treat-
ment of cancer. The present review critically analyzes the use of extracellular pH targeting for
nanogels, siRNA delivery, PEGylated nanogels, multi-responsive nanogels and intracellular deliv-
ery of nanogels for improved therapy of cancer.
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There has been considerable work on hydrogels, which are
described as hydrophilic three dimensional polymer networks
that are able to take up large amounts of water or physiolog-
ical ﬂuid, while maintaining their internal network structure
(Peppas et al., 2000; Bromberg, 2005; Raemdonck et al.,
2009a). In the last decade there has been increasing interest
in hydrogels conﬁned to nanoscopic dimensions (nanogels).
Nanogels can be designed to facilitate the encapsulation of
diverse classes of bioactive compounds and following applica-
tions of nanogels show their utility as a potential nanomedi-
cine carrier:
1. Upon intravenous injection, nanogels can reach the
areas which are not easily accessed by hydrogels.
2. Nanogels are ideal candidates for intracellular delivery
and can be safely delivered into the cytoplasm of the cell
(Toita et al., 2011).
3. Nanogel dispersions have a larger surface area which is
important for in vivo applications.
4. Nanogels have sizable drug loading capacity, low buoy-
ant density and high dispersion stability in aqueous
media.
5. Nanogels enhance the efﬁcacy of therapeutic nucleoside
analogs (Vinogradov et al., 2005).
6. Nanogels can encapsulate delicate compounds with low
or high molecular weights and can signiﬁcantly prolong
their activity in biological environments (Bae et al.,
2008).
7. Weakly cross-linked polyelectrolyte nanogels can incor-
porate biomacromolecules of the opposite charge.
Whereas; biomacromolecules are not able to accommo-
date in hydrogels due to the effects of excluded volume
and cross-linking density (Kabanov and Vinogradov,
2009).
8. Nanogels can be chemically modiﬁed to incorporate var-
ious ligands for targeted drug delivery, triggered drug
release or preparation of composite materials
(Vinogradov et al., 2002).
9. Nanogels can be used for efﬁcient delivery of biophar-
maceuticals in cells as well as for increasing drug deliv-
ery across cellular barriers (Park et al., 2010).Figure 1 3D structure of nanogels.10. The nanoscale dimension of nanogels makes them to
respond rapidly to environmental changes such as pH
and temperature.
Nanogels show promise as a suitable nanomedicine carrier
as compared to other nanoparticles especially in terms of drug
loading (Fig. 1). Nanogels can be prepared or synthesized even
in the absence of the drug to be loaded as drug loading in
nanogels can be efﬁciently done later on when the nanogels
are swollen and equilibrated in water or biological ﬂuid. Drug
loading occurs spontaneously in nanogels. As compared to
other conventional nanoparticles, nanogels allow much higher
drug loading (up to 50% of weight). Moreover the methods of
preparation of nanogels are simpler and do not involve the use
of mechanical energy or organic solvents (Vinogradov et al.,
2004). Hence the loaded drug or therapeutic is not exposed
to any vigorous condition during preparation. After adminis-
tration the nanogels safely carry the payload, move within
the cells and release the contents in the desired place in vivo.
Two of the approaches most commonly used for prepara-
tion of nanogels are physical self-assembly of interactive poly-
mers and chemical cross-linking of preformed polymers (Oh
et al., 2007). The physical self-assembly of polymers involves
controlled aggregation of hydrophilic polymers capable of
bonding with each other. Physical cross-linking in nanogel for-
mation occurs via non-covalent attractive forces, such as
hydrophilic–hydrophilic, hydrophobic–hydrophobic, ionic
interactions and/or hydrogen bonding (Yallapu et al., 2011).
The formation of nanogels occurs within a few minutes after
suitable association of amphiphilic block copolymers and com-
plexation of oppositely charged polymeric chains.
The preparation of nanogels is conducted in mild condi-
tions and in aqueous media. According to Kabanov and
Vinogradov (2009) ‘‘Self-associating hydrophilic polymers
allow encapsulation of biomacromolecules and are useful for
preparation of protein-loaded nanogels’’. Chemical crosslink-
ing is a method for creating nanogel with large pore sizes
(Vinogradov, 2006). Crosslinks have to be present in a hydro-
gel in order to prevent dissolution of the hydrophilic polymer
chains in aqueous media. Labile bonds are frequently intro-
duced into hydrogels to make them biodegradable
(Raemdonck et al., 2009a,b). Degradable bonds such as ester,
carbonate, amide, anhydride, phosphazene and phosphate
esters, are inserted either in cross-linkers or in polymeric
chains for allowing degradation of the nanogel network.
Although the hydrophilic nature of nanogels may offer lim-
itation for encapsulation of hydrophobic drugs; suitable engi-
neering of the polymer structure allows high encapsulation of
poorly soluble anticancer drugs (Soni and Yadav, 2014).
Poorly soluble anticancer drugs can also be incorporated into
nanogels for improving their solubility and stability thereby
increasing their chances of cellular uptake than the free drug.
In a study by Li et al. two poorly soluble anticancer drugs,
paclitaxel (PTX) and 10-hydroxycamptothecin were loaded
in nanogels by shell cross-linking of Pluronic F127 micelles
(Li et al., 2011). The nanogels had a smooth and distinct
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polymer matrix.
Nanogels hold promise to be a versatile drug delivery car-
rier for utilization in different therapeutics, as already dis-
cussed in many review articles (Lee et al., 2008; Liechty and
Peppas, 2012; Chacko et al., 2012; Gonc¸alves et al., 2010). This
expert review will speciﬁcally focus on the recent developments
in the use of nanogels for tumor-targeting.
2. Nanogels for loading siRNA
A small interfering RNA (siRNA) is a class of double-stranded
RNA molecules consisting of 21–23 nucleotides, involved in
inhibition of protein synthesis encoded by the messenger
RNAs (mRNA) (Dykxhoorn et al., 2006). The siRNA medi-
ates posttranscriptional gene silencing of a speciﬁc target pro-
tein by disrupting mRNA when introduced into cells (Oliveira
et al., 2006). They show promise to be used for any disease-
causing gene as well as for targeting any cell or tissue
(Reischl and Zimmer, 2009). siRNA as a gene regulating tool
has a tremendous therapeutic potential in the areas of cancer
treatment.
However, the clinical application of siRNA is hindered by
its poor stability (Cun et al., 2010), degradation by endogenous
enzymes (Singha et al., 2011), low cellular uptake efﬁciency,
low endosomal escape efﬁciency (Xie et al., 2006) and short
half-life in blood (Morrissey et al., 2005). Also the naked siR-
NA is unable to penetrate cellular membranes due to its large
size and high negative charge. Such obstacles restrict the deliv-
ery of siRNA in vivo and require a suitable delivery carrier.
Among different carriers, nanogels show promise as a novel
transport medium for siRNA.
Dickerson et al. suggest targeted delivery of siRNAs by
nanogels may be a promising strategy to increase the efﬁcacy
of chemotherapy drugs for the treatment of cancer
(Dickerson et al., 2010).
It is difﬁcult to load siRNA into nanogel carrier with high
encapsulation efﬁciency as it easily leaks from the carrier due
to its hydrophilic character. To increase siRNA loading efﬁ-
ciency it is complexed with cationic excipients to enhance the
afﬁnity between the siRNA and the particle matrix. Mimi
et al. used polyethyleneimine (PEI) nanogels as an effective
siRNA carrier. The negative charge of siRNA allows it to form
a strong electrostatic interaction with the positively charged
polyethyleneimine (Mimi et al., 2012). The consequential poly-
ionic complexes also protect siRNA against enzymatic degra-
dation. Other negatively charged complexing agents used are
di oleyltrim ethyl ammonium propane and polyamines.
Chitosan has been shown to be useful as a carrier for
improving the cellular uptake of naked siRNA both in vitro
and in vivo via different administration routes (Mao et al.,
2010). Chitosan is also useful for preventing the rapid degrada-
tion of siRNA in vivo.
Lee et al. explored the potential possibility of Hyaluronic
acid as a biocompatible and biodegradable nanogel for deliv-
ery of siRNA. These nanogels crosslinked with disulﬁde link-
ages showed target-speciﬁc intracellular delivery of siRNA to
HA-speciﬁc CD44 receptor over-expressing cancer cells (Lee
et al., 2007).
Cationic dextran hydroxyethyl methacrylate (dex-HEMA)
based nanogels are promising carriers for siRNA delivery sincethey can be loaded efﬁciently with siRNA, taken up by cells
in vitro and were able to deliver intact siRNA into the cytosol
of cells (Raemdonck et al., 2009b). Raemdonck et al. used the
photopolymerization method to load siRNA into dextran
nanogels (dex-HEMA-co-TMAEMA) using UV induced
emulsion (Raemdonck et al., 2010). These nanogels were used
as a siRNA depot from which siRNA released at the desired
time to prolong the gene silencing effect. It was reported that
in this way the siRNA dose was more efﬁciently deployed.
Photochemical internalization was used as a trigger to induce
endosomal escape of siRNA through the use of amphiphilic
photosensitizers.
Naeye et al. PEGylate cationic dex-HEMA nanogels by
covalent attachment of NHS-PEG to the reactive amine
groups of the nanogels with an aim to deliver siRNA in vivo
(Naeye et al., 2010). It was shown that dex-(HE)-MA-co-
AEMA-co-TMAEMA nanogels retained their high loading
efﬁciency of siRNA after PEGylation. The diffusion of the
negatively charged siRNA molecules inside the gels occurred
very slowly and that the siRNA was trapped by the cationic
charges in the nanogels. Also, siRNA-loaded PEGylated
dex-(HE)MA-co-AEMA-co-TMAEMA nanogels were able
to successfully down regulate EGFP without causing severe
toxicity in a HuH-7 EGFP cell line.
3. PEGylated nanogels
PEGylation refers to the modiﬁcation of a particle surface by
covalently grafting, entrapping or adsorbing polyethylene gly-
col (PEG). PEGylated nanoparticles are long circulating mak-
ing the drug available for a prolonged period of time (Yadav
et al., 2011a). PEGylation of nanogels not only improves their
circulation time but also delivers their drug load into tumors
following intravenous injection.
PEGylated nanogels are also prepared by chemically cross-
linking poly(2-N,N-(diethylamino)ethyl methacrylate)
(PEAMA) gel cores surrounded by PEG palisade layers. The
PEGylated nanogels showed high stability under extremely
dilute and high salt conditions, in contrast to self-assembled
nanocarriers. Moreover, the nanogels showed pH-dependent
swelling/deswelling transitions across the pKa of the PEAMA
gel core around pH 7.0. Such nanogels swell under acidic con-
ditions and they deswell under alkaline conditions.
Shimoda et al. chemically crosslinked nanogels with
polyethylene glycol (PEG) derivatives to overcome the insta-
bility of physically crosslinked nanogel in vivo (Shimoda
et al., 2012). Polysaccharide–PEG hybrid nanogels
(CHPOA–PEGSH) were crosslinked by both covalent ester
bonds and physical interactions by the reaction of a
thiol-modiﬁed poly(ethylene glycol) (PEGSH) with acry-
loyl-modiﬁed cholesterol-bearing pullulan (CHPOA). The
formulations were injected intravenously in mice to study
their blood clearance. CHP nanogels were eliminated from
the blood within 6 h, whereas the CHPOA–PEGSH
nanogels had a signiﬁcantly longer circulation time: approx-
imately 40–50% of the nanoparticles remained in circulation
6 h following injection and, after 24 h, 20–30% of the
nanoparticles remained in the blood. The half-life of
CHPOA–PEGSH nanoparticles was about 15-fold greater
than that of CHP nanogels indicating long circulation
behavior of PEGylated nanogels.
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Intracellular drug delivery refers to the delivery of therapeutic
agents to speciﬁc compartments or organelles within the cell
(Yadav et al., 2011b). This targeted intracellular drug delivery
results in higher bioavailability of a therapeutic agent at its site
of action, increases the pharmacologic effect and reduces the
side effects of the drug (Panyam and Labhasetwar, 2004).
Studies such as intracellular delivery, cytotoxicity, cellular
uptake hold promise for cancer chemotherapeutics. Nanogels
due to their small size offer intracellular delivery of therapeutic
molecules with respect to cellular uptake via endocytosis and
the enhanced permeation and retention (EPR) effect (Ayame
et al., 2008).
Choi et al. (2010) developed a novel self-assembled heparin-
Pluronic nanogel incorporating RNase A for intracellular
delivery of proteins. Their investigation showed that the nano-
gel was more efﬁciently internalized into HeLa cells and even
localized to the nucleus (Fig. 2). The uptake mechanism
reported was via caveolae/lipid-raft-mediated endocytosis.
The nucleus penetration of heparin-based nanogels exhibited
signiﬁcant cytotoxicity that was dependent on the concentra-
tion of RNase A.
In a study by Murphy et al. (2011) drug-loaded nanogels
showed enhanced potency when compared to free drug after
exposure to M21 cells. There was an important ﬁnding that
the EC50 values of the cells exposed for 20 min with the nano-
gels were comparable with the cells exposed to the free drug for
72 h. Oh et al. (2010) prepared a pH-responsive self-organized
nanogel loaded with DOX and evaluated their cytotoxicity
against A2780 cell lines.
Huang et al. (2009) used PF127 to produce amphiphilic
nanocarriers for doxorubicin (DOX). In order to stabilize
the nanocarriers, the hydroxyl groups on both termini of
PF127 were acrylated and reacted with methacrylated chon-
droitin sulfate (CSMA) to form CS-PF127.
The better cellular internalization of FA-CS-PF127 into the
FR overexpressing KB cells was evidenced by CLSM and ﬂow
cytometry. Flow cytometry analysis was applied to check the
targeting efﬁciency of the FA-modiﬁed nanogel (FA-CS-
PF127) and to investigate the cellular uptake in FR-positive
KB cells. It was shown that FA-CS-PF127 nanogels enteredFigure 2 Intracellular uptake of HP nanogels: (A) Confocal image o
RNase A (red), (B) Locolization of RNase A (red), Nucleus is stainedinto KB cells efﬁciently and this FA targeting moiety was
responsible for the better internalization into KB cells.
Li et al. (2011) prepared paclitaxel (PTX) loaded nanogel
using shell cross-linking of Pluronic F127 micelles with poly-
ethylenimine (PEI) (F127/PEI nanogel). The cytotoxicity of
PTX-loaded F127/PEI nanogel was investigated using
HEPG-2 cells. The IC50 value data suggested that PTX-loaded
nanogel displayed higher cytotoxicity compared with that of
the free drug. The empty folate modiﬁed F127/PEI nanogel
did not show signiﬁcant toxicity in the whole concentration
range compared with the free PTX. The folate-modiﬁed
PTX-loaded nanogel demonstrated a signiﬁcantly superior
cytotoxicity as it has a much lower IC50 value. Folate-mod-
iﬁed PTX-loaded nanogel was uptaken efﬁciently into
HEPG- 2 cells than the non-modiﬁed F127/PEI nanogel
due to the interaction between the folate on the nanogel
surface and the folate receptors on the HEPG-2 cell sur-
face. This interaction ensured that more drugs were
pumped into the tumor cells to give a better anti-cancer
effect.
5. Nanogel for tumor extracellular pH Targeting
Differences in pH between healthy tissue and tumor tissue can
be exploited as an internal stimulus for triggered drug release
(Oerlemans et al., 2010). Due to the high rate of aerobic and
anaerobic glycolysis in the cancer cells, the pH of tumor tissue
is slightly lower (pH 6.8) than the healthy tissue (pH 7.4).
Oh et al. (2010) utilized glycol chitosan (GCS) to prepare a
novel pH-responsive drug-carrying system that recognized
tumor pH. The pH sensitivity was provided by grafting 3-
diethylaminopropyl isothiocyanate (DEAP) to GCS. The
pKb of DEAP ranges from 7.0 to 7.3 which is similar to tumor
pH. The GCS-g-DEAP conjugate was used to prepare pH-
responsive self-organized nanogel loaded with doxorubicin
(DOX). The release of DOX was enhanced at pH 6.8 com-
pared to that at normal pH 7.4, signifying higher concentra-
tion of DOX at cancer sites with an acidic pH (pH 6.8)
(Fig. 3A). Such nanogel would therefore maximize the
therapeutic activity of the drug for treatment of in vivo cancers.
It was suggested that DOX loaded GCS-g-DEAP nanogels
could be successfully used for targeting cancer-associatedf HeLa cells incubated with HP nanogels with Alexa 488-labeled
in blue (Ref. Choi et al., 2010).
Figure 3a pH-dependent DOX release from DOX-loaded GCS-
g-DEAP nanogels at pH 7.4 (O), pH 6.8 (m), and pH 6.0 (d) for
0–24 h of incubation (Ref. Oh et al., 2010).
Figure 3b pH-dependent ORI release from ORI- loaded nano-
gels at different pH (Ref. Duan et al., 2011).
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release at endosomal pH (i.e., pH 6.0).
Na et al. fabricated DOX loaded self-organized nanogels
composed of hydrophobized pullulan (PUL)-Na-Boc-l-histi-
dine (bHis) conjugates (Na et al., 2007). Nanogels showed
tumor speciﬁc release of DOX which increased signiﬁcantly
with reductions in pH.
Tumoral acidic extracellular pH targeting was exploited for
oridonin (ORI), a hydrophobic anticancer drug in Chinese tra-
ditional medicine (Duan et al., 2011). A pH-responsive chito-
san-g-poly(N-isopropylacrylamide) (CS-g-PNIPAm) based
nanogel delivery system was developed by a self-assembly
method. ORI-loaded nanogels exhibited a pH-triggered fast
drug release under a slightly acidic condition. The drug release
was slow at pH 7.4 while it accelerated at lower pH of 6.5 and
6.0 (Fig. 3B). ORI-loaded nanogels showed a higher cellular
cytotoxicity relative to the ORI solution at the same pH.
The anticancer cytotoxicity of ORI-loaded nanogels against
HepG2 cells was signiﬁcantly increased at pH 6.5 compared
to that at pH 7.4. Moreover, the IC50 value for the ORI-loaded
nanogels was lower (8.86 lg/ml) at pH 6.5 as compared to pH
7.4 (13.19 lg/ml) indicating a pH-dependent effect. This was
attributed to the pH sensitive rapid drug release of drug at
lower pH.
6. Stimuli-responsive nanogels
Nanogels exhibiting a phase transition in response to change in
external conditions such as pH, ionic strength, temperature or
electric currents are known as ‘‘stimuli-responsive’’ nanogels.Nanogels swell due to solvent penetration into free spaces
and this swelling behavior is inﬂuenced by external triggers,
such as changes in environmental pH, ionic strength or tem-
perature. Nanogels show much faster responsiveness as com-
pared to the conventional hydrogels. Multi-stimuli responsive
nanogels are more effective in targeted therapy for cancer as
compared to single responsive nanogels (Morinloto et al.,
2008; Rijcken et al., 2007).
Among multi-stimuli responsive drug vehicles, dual temper-
ature-/pH-stimuli responsive carriers ﬁnd wider application in
cancer therapy because in cancer there are changes in the tem-
perature and pH of body tissue and these two signals could be
regulated easily by external triggers (Zhang et al., 2007). Xiong
et al. (2011) prepared dual temperature-/pH-sensitive poly(N-
isopropylacrylamide-co-acrylic acid) nanogels (PNA), and
conjugated DOX onto PNA nanogels via acid-cleavable bonds
(DOX–PNA). The PNA nanogels were hydrophilic under
physiological condition, but underwent a dual temperature/
pH induced phase transition upon heating through its LCST,
which was affected by the pH value (Fig. 4). This difference
in pH between tumor and normal tissues allowed cancer cellu-
lar internalization under region hyperthermia treatments. The
drug loaded nanogel cleaved upon mildly acidic triggering in
the endosome of tumor cells to release DOX. It was shown
that such dual temperature-/pH-sensitive DOX–PNA nanogels
would have better tumor targeted delivery than common tem-
perature sensitive materials.
Qiao et al. prepared a new type of triply responsive nano-
gels by mini emulsion radical copolymerization of monomethyl
oligo(ethylene glycol) acrylate and ortho ester-containing
acrylic monomer, 2-(5,5-dimethyl-1,3-dioxan-2-yloxy) ethyl
acrylate, with bis(2-acryloyloxyethyl) disulﬁde as a crosslinker
(Qiao et al., 2011). The thermo/pH/redox responsive behavior
of the nanogels is depending on the composition and crosslink-
ing of the polymer. These nanogels were able to encapsulate
the hydrophobic drug paclitaxel (PTX), had good stability at
pH 7.4 and showed potential cytotoxicity to tumor cells.
Chen et al. have recently reported an injectable dual-
responsive micellar nanogel system for controlled delivery of
PTX in cancer therapy (Chen et al., 2013). The micellar nano-
gel improved the solubility and stability of PTX. The dual-
responsive micellar nanogel showed sol–gel transition at
37 C. The in vitro PTX release showed that nanogel could
release about 70% for 70 h under pH 5.0 while about 10%
release at pH 7.4 and pH 9.0. The dual-responsive micellar
nanogel suppressed tumor growth and showed potential as a
dual-responsive drug delivery system for cancer therapy.
Kim et al. loaded doxorubicin in polypeptide-based nano-
gels with hydrophobic moieties in the cross-linked ionic cores
(Kim et al., 2013). The nanogels had high drug loading capac-
ity of 30 w/w% and were of considerably small size of 70 nm in
diameter. The nanogels were found to be enzymatically
degradable leading to accelerated drug release under simulated
lysosomal acidic pH. The doxorubicin loaded nanogels showed
improved antitumor activity compared to a free doxorubicin in
an ovarian tumor xenograft mouse model signifying the use of
such biodegradable nanogels as attractive carriers for delivery
of chemotherapeutics. Doxorubicin was also loaded in chitin
nanogels having pH sensitive controlled release (Jayakumar
et al., 2012). The drug release studies showed that doxorubicin
release was more in acidic pH compared to neutral pH. In the
ﬁrst hour 32% doxorubicin was released, which was similar in
Figure 4 Tumor extracellular pH targeting by nanogels (Ref. Xiong et al. (2011)).
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released under acidic condition, whereas only about 40%
was released in the neutral environment. This difference in
release was attributed to higher swelling of nanogel in acidic
pH. Yet again in another study doxorubicin was loaded in dual
stimuli-responsive hollow nanogel spheres for pH dependent
intracellular delivery (Chiang et al., 2012). The nanogels exhib-
ited a pH-controlled drug release proﬁle in an aqueous solu-
tion at 37 or 4 C. The cumulative drug release performed at
pH 5.0 over a period of 3 h (50%) was much higher than that
(20%) at pH 7.4. The delivery system demonstrated promise in
intracellular drug release for transport within acidic endo-
somal or lysosomal compartments.
7. Expert opinion and conclusion
Recent years have witnessed an extraordinary expansion in
drug delivery research in the area of cancer. There is an
increasing assurance that nanotechnology applied to medicine
will bring signiﬁcant advances in the diagnosis and treatment
of cancer. When most of the chemotherapeutics fail to show
effect clinically in the treatment of cancer due to their toxic
side effects, nanogels as nanomedicine yield more effective
therapies.
Nanogels are being explored as drug delivery agents for tar-
geting cancer due to their easy tailoring properties and ability
to efﬁciently encapsulate therapeutics of diverse nature
through simple mechanisms. Nanogels are proﬁciently inter-
nalized by the target cells, avoid accumulating in non-target
tissues thereby lower the therapeutic dosage and minimize
harmful side effects.
Although, the last decade has witnessed intensive research
in the nanogel formulations some factors are slowing the pro-
cess of industrial production of the same. These factors include
inefﬁcient translation of in vitro properties to in vivo efﬁcacy,
toxicity concerns, immunogenicity, pharmacokinetics of
in vivo models, biodistribution and regulatory issues. There is
an urgent need for relevant clinical data from nanogels so as
to allow translation of the nanogel concept into a viable ther-
apeutic application for treatment of cancer. Nanogels as a
drug delivery carrier would improve the efﬁcacy of cancer
chemotherapy and beneﬁt of the cancer patients.
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